Introduction: The diagnostic utility of in vivo amyloid b (Ab) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Ab in pathologically confirmed FTD syndromes. Methods: Ab was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of 11 C-Pittsburgh compound B (PiB)-positron emission tomography imaging was assessed in a subset of FTD cases (n 5 15). Results: Ab was identified in a similar proportion of FTD syndromes and age-matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Ab with PiB standard uptake value ratio scaled to the white matter. Discussion: The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.
Introduction
Frontotemporal dementia (FTD) and Alzheimer's disease (AD) are the leading causes of dementia in individuals aged less than 65 years. Despite being characterized by distinct underlying pathologic proteins and spread, the clinical distinction between FTD and AD remains challenging, with w25% of patients with a clinical FTD syndrome found to have a pathologic diagnosis of AD at autopsy [1] . Although this is largely driven by patients with the logopenic variant of primary progressive aphasia (lv-PPA), AD is also found in a significant proportion of patients with other FTD syndromes, including the non-fluent variant of primary progressive aphasia (nfv-PPA), corticobasal syndrome (CBS), semantic variant of primary progressive aphasia (sv-PPA) and behavioral variant frontotemporal dementia (bvFTD) [1, 2] . Research diagnostic criteria for clinical AD have recently incorporated in vivo markers of amyloid b (Ab) pathology such as positron emission tomography (PET) with the 11 C-Pittsburgh compound B (PiB) ligand. Amyloid ligands appear to be particularly helpful in identifying patients with AD pathology and may be of particular value in atypically presenting AD cases such as those with lv-PPA or CBS [3] . Importantly, these ligands correlate with overall Ab burden rather than only neuritic plaques [4] [5] [6] , but given that only neuritic plaques were used for diagnostic confirmation of AD before the publication of the updated pathologic criteria for AD in 2012 [7] [8] [9] , pathologic data on the prevalence and burden of Ab in FTD syndromes are lacking. This could have important implications for the use and interpretation of PiB-PET imaging to differentiate pathologic AD in patients presenting with clinical FTD syndromes. To address this, the present study had the following aims: (1) to determine the proportion of Ab positivity, Thal's topographical distribution [7] and clinical implications of Ab deposition in a large cohort of pathologically confirmed FTD syndromes that do not meet the threshold for intermediate or high levels of AD neuropathology; (2) to determine if in vivo and postmortem measures of Ab burden correlate in FTD; and if so, (3) to assess histological Ab burden in patients with FTD 75 years at death (since PiB-PET imaging assessments are performed aged 75 years in clinical FTD), with the purpose of determining whether FTD cases demonstrate a Ab burden similar to pathologic AD.
Methods

Cohort
One hundred thirty-four cases comprising 98 pathologically confirmed FTD and 36 cognitively normal individuals were selected from neuropathologic series collected by the Sydney Brain Bank and the Cambridge Brain Bank through regional brain donor programs. These brain donor programs hold approval from the Human Research Ethics Committees of the University of New South Wales, South Eastern and Illawarra Area Health Service, and the Addenbrooke's Hospital. Patients were diagnosed during life by experienced clinicians using standard clinical diagnostic criteria [10] following a medical interview, cognitive testing, and an informant history. Standardized neuropathologic characterization was performed [7, [11] [12] [13] [14] [15] [16] . Cases were excluded if they had moderate or severe cortical neuritic plaque formation (2 modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] score [7] ) and neocortical neurofibrillary tangles (NFTs) (2 modified Braak NFT score [7] ). This research project was approved by the Human Research Ethics Committee of the University of New South Wales.
Genetic analyses
Patients were screened for genetic mutations (C9ORF72, GRN, PSEN1, and APP) using previously published methods [17] .
Topographical distribution of amyloid b
Formalin-fixed, paraffin-embedded tissue blocks for the left frontal cortex, temporal cortex, caudateputamen, and substantia nigra were sectioned at 10 mm and immunostained with an anti-Ab monoclonal antibody (1:500, M0872; DAKO) according to the updated NIA guidelines [7] . All slides were counterstained with hematoxylin to visualize neurons and other cells. Ab deposition was graded using the recommended A score, which is the topographical progression according to the modified Thal scoring scheme: A0 5 no detectable deposition (Thal phase 0), A1 5 any cortical Ab deposition (Thal phase 1-2), A2 5 any Ab also present in the caudate-putamen (Thal phase 3), and A3 5 any Ab present in the cortex, caudate-putamen, substantia nigra, and cerebellum (Thal phase 4-5) [7] .
PiB-PET assessments
Fifteen autopsy cases that had undergone in vivo PiB-PET and were followed to autopsy were available for this study. All had a clinical diagnosis of a FTD syndrome before imaging, but four (27%, 4/15) were excluded from the previous cohort as they had pathologic AD at autopsy. PET imaging had been performed at the Austin Hospital in Melbourne as previously described [18] . Global and regional standardized uptake value ratios (SUVRs) were obtained from regions of interest (ROIs) for cortical, subcortical, and cerebellar regions defined on a coregistered magnetic resonance imaging, regions corresponding to the Thal stages of Ab deposition [7] . White matter ROIs were placed at the centrum semiovale, and the cerebellar regions were placed over the cerebellar cortex, taking care to avoid white matter. The orbitofrontal ROI included both the mesial and lateral aspects (including superior, middle, and inferior frontal gyri). Cortical Ab burden was expressed as the average SUVR of the area-weighted mean of frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate regions. Consistent with previous PiB-PET studies [18] [19] [20] , an SUVR Cb cutoff of 1.50, using the cerebellar cortex as the reference region, was employed for the categorical classification of patients into a "high" or "low" PiB retention. However, given that Ab deposition is recognized in the cerebellum of a proportion of patients with an A3 score (Thal phase 5) [7, 21] , we assessed which reference region-derived SUVR agreed best with the neuropathology. That is, correlations between the amount of pathologic Ab deposition and the SUVR scaled to four reference regions (cerebellar cortex, pons, white matter [centrum semiovale], and a composite of white matter and pons) were performed.
Volume fraction of amyloid b
Volume fraction analysis was performed in all autopsy cases with PiB-PET to assess the association between SUVR and neuropathology (Section 3.3). Volume fraction analysis was also assessed across all pathologically confirmed FTD and control cases that were 75 years at death and that had Ab deposition, and a comparative cohort of AD cases without cerebrovascular disease and 75 years at death. The age cutoff of 75 years was applied to reflect in vivo conditions because almost all patients with clinical FTD undergo PiB imaging at the age of 75 years. Ab-immunostained slides were scanned using the Aperio ScanScope XT slide scanner, and the volume fraction of histological Ab deposits was calculated using a point-counting method as previously described [22] (Supplementary Material) by two raters blind to case details with inter-and intra-rater variances of ,5%.
Statistical analyses
Statistical analyses were performed using SPSS (version 21). Demographic data (age, sex, and postmortem delay), clinical (disease duration, CDR score) variables, and volume 
Braak NFT stage (B0-B3) [7] 0.3 6 0.6 0.1 6 0.4 0.4 6 0.6 0.2 6 0.4 0.5 6 0.8 CERAD score (C0-C3) [7] 0.3 6 0.8 0.2 6 0.6 0.2 6 0.5 0.1 6 0.3 0.2 6 0.6 ABC AD score (0-3) [7] 0.6 6 0. fraction of Ab were assessed across participant groups via one-way analysis of variance (ANOVA) followed by Bonferroni-corrected post hoc tests (P , .05 taken as significant). c 2 analyses were used to compare the proportion of cases with Ab deposition and the topographical distribution of Ab deposition between participant groups. Pearson's correlation coefficient was used to assess for associations between demographic features, clinical indices, and the topographical distribution of Ab within groups. Pearson's correlation coefficient was also used to assess associations between regional Ab deposition and regional SUVR measures scaled to each of the four reference regions (one analysis per reference region), with corrections for multiple testing using false discovery rate (P , .03 taken as significant). Accuracy was determined as the proportion of cases with matching diagnoses.
Results
Cortical amyloid b in pathologically confirmed FTD and controls
All cases were graded according to the "ABC" score for AD neuropathologic change [7] and cases that met a no or low "ABC" score selected (n 5 94 FTD, n 5 26 controls). Given that the control cases were significantly older than the FTD cohort (mean 6 standard deviation [SD] [years]: FTD 69 6 9, controls 81 6 14; P , .001), an age cutoff of 85 years at death was applied to the control cohort to select an age-matched control subset (mean 6 SD (years): agematched controls 71 6 10; P . .05 compared to FTD cases).
Cortical Ab deposition was identified in 37% (35/94) of FTD and 57% (8/14) of the age-matched control subset (and 77% [20/26] of the entire control cohort). FTD cases with Ab were older at disease onset and death but demonstrated no significant difference in disease duration, CDR or FTD stage (Supplementary Material). The topographical progression of Ab increased with age at death (r 5 0.410, P , .001, n 5 94) and disease onset in FTD (r 5 0.389, P , .001, n 5 94). No significant relationship was identified between CDR scores and any measured pathologies in FTD cases. A positive correlation was observed between age at death and the topographical distribution of Ab across all control cases (r 5 0.616, P , .001, n 5 36) but not within the agematched control subset (r 5 0.324, P 5 .258, n 5 14). (Fig. 1) . In both bvFTD and PPA groups, the topographical progression of Ab increased with age at death (bvFTD: r 5 0.448, P 5 .001, n 5 56; PPA: r 5 0.38, P 5 .19, n 5 38) and disease onset (bvFTD: r 5 0.375, P 5 .004, n 5 56; PPA: r 5 0.412, P 5 .12, n 5 38) (Fig. 1) . Fig. 2 . The proportion of Ab positivity and topographical distribution of Ab in frontotemporal dementia (FTD) syndromes with and without motor impairment. The proportion of patients that demonstrate no Ab deposition (A0), Ab in the frontal-temporal cortices (A1), additional Ab in the basal ganglia (A2), and additional Ab in the substantia nigra (A3) is shown in patients with behavioral variant FTD cases without motor impairment (bvFTD), primary progressive aphasia cases without motor impairment (PPA), cases with motor neuron disease (MND), and cases with extrapyramidalism. As only one PPA case without motor impairment had an A3 distribution (4%, 1/26), this has been combined with the A2 group.
Amyloid b in FTD cases with and without motor impairment
Co-existing motor neuron disease (MND) was present in 21% bvFTD (12/56) and 16% PPA cases (6/38). An extrapyramidal syndrome (CBS/progressive supranuclear palsy [PSP]) was present in a further 21% bvFTD (12/56) and 16% PPA cases (6/38). The age at disease onset, disease duration, and age at death were similar across motor subgroups both within and across the bvFTD and PPA cohorts (Supplementary Material). Collectively, across all FTD cases, the proportion of cases with Ab deposition was similar between motor subgroups, with Ab identified in 36% FTD cases (21/58), 28% FTD-MND cases (5/18), and 50% FTD-extrapyramidal cases (9/18) (Fig. 2) .
Amyloid b in FTD cases with and without genetic mutations
Among FTD cases, a C9ORF72 expansion was identified in 11% (10/94), a GRN mutation in 7% (7/94), and a MAPT mutation in 4% (4/94) ( Table 1) . FTD cases without a mutation were older at death, but this only reached significance in comparison to cases with a GRN mutation (mean 6 SD (years): no mutation 70 6 8, C9ORF72 expansion 65 6 9, GRN mutation 60 6 5, and MAPT mutation 60 6 4; F(3,88) 5 5.254, P , .05 with post hoc tests identifying P 5 .021 for GRN versus no mutation only). Ab deposition was identified in 40% of FTD cases without a mutation (bvFTD: 16/38 and PPA: 13/35), 20% of cases with a C9ORF72 expansion (bvFTD: 2/9 and PPA: 0/1), 43% of cases with a GRN mutation (bvFTD: 3/5 and PPA: 0/2), and 0% of cases with a MAPT mutation (Fig. 3) . No significant difference was identified in the proportion [X(3) 5 4.036, P 5 .258, n 5 94] or topographical distribution [X(9) 5 9.410, P 5 .400, n 5 94] of Ab between mutation groups in FTD cases.
PiB-PET SUVR and amyloid b pathology in clinical FTD syndromes
Of the 15 patients with antemortem PiB-PET, postmortem characterization revealed FTD pathology in 73% (11/15) and high levels of AD pathology sufficient to reach a pathological diagnosis of AD in 27% (4/15) ( Table 2) . We assessed the relationship between (1) the degree of Ab deposition with the categorical classification of a high/low PiB based on a SUVR Cb cutoff of 1.50 and (2) the volume fraction of histological Ab with cortical SUVR scaled to four different reference regions. Fig. 3 . The proportion of Ab positivity and topographical distribution of Ab in frontotemporal dementia (FTD) cases with and without a genetic mutation. The proportion of patients that demonstrate no Ab deposition (A0), Ab in the frontal-temporal cortices (A1), additional Ab in the basal ganglia (A2), and additional Ab in the substantia nigra (A3) is shown in FTD cases without a mutation (n 5 55), a MAPT mutation (n 5 4), a C9ORF72 expansion (n 5 10), and a GRN mutation (n 5 7) is shown. As only one FTD case without a mutation had an A3 distribution (1%, 1/73), this has been combined with the A2 group.
Categorical classification
At the time of PiB-PET imaging, four patients had a high SUVR Cb of .1.5 (#11, #13, #14, and #15) and all four of these patients had severe Ab deposition (PiB accuracy of 100%), although one (#11) did not have sufficient NFT formation for a neuropathologic diagnosis of AD [7] . A SUVR Cb of 1.25 was determined in one patient (#12 who progressed to have high levels of AD pathology at death), and SUVR Cb ,1.2 were observed in all other patients (10 FTD), including two pathologic FTD cases with moderate cortical Ab deposition at autopsy (#3 and #10, Table 2 ). Overall, in cases with a low SUVR Cb ,1.5, 73% (8/11) demonstrated no Ab deposition in the frontal and temporal cortices, and 91% (10/11) did not meet pathologic criteria for a diagnosis of AD at autopsy.
Volume fraction of amyloid b and SUVR in patients with a clinical FTD syndrome
The volume fraction of Ab in the frontal cortex, temporal cortex, and striatum of patients found to have Ab pathology in these regions at autopsy (7/15 patients) was assessed against the corresponding regional SUVR scaled to four reference regions. This analysis was performed across cases and regions with Ab deposition at autopsy, using data from all regions with Ab pathology. Correlation analyses revealed a significant positive association between regional histological volume fractions of Ab with SUVR scaled to the white matter (centrum semiovale) (r 5 0.659; P 5 .014) (Fig. 4) , but not to the corresponding regional SUVR scaled to the cerebellum (r 5 0.457; P . .5), pons (r 5 0.513; P . .5) nor to the composite of white matter and pons (r 5 0.598; P 5 .031). Table 3 ). Given that the volume fraction of Ab deposition in the frontal and temporal cortices was similar within all groups (P . .05 for all), an average of these two regions was taken to calculate the burden of cortical Ab, which was found to be significantly different across groups [F(3,32) 5 17.062; P , .001 due to a significantly greater burden of cortical Ab in AD cases (P , .001: AD compared to all other groups) (Fig. 5 ).
Discussion
Although a pathologic diagnosis of AD accounts for w25% of patients with an FTD syndrome [1] , the pathologic assessment of Ab in the remaining w75% of patients Table 2 PiB-PET and postmortem pathologic assessment in patients with FTD Number Clin dx A score [7] Braak NFT score [7] CERAD neuritic score [7] ABC score [7] 1 nfv-PPA No with FTD, particularly, in patients that have also undergone in vivo PiB-PET imaging is scarce. The present study assesses a large pathologic series of FTD syndromes without AD and reports Ab deposition in 38% (21/56) in patients with bvFTD, 37% (14/38) in patients with PPA, and 57% (8/14) in age-matched controls. The presence and topographical progression of Ab increased with age in FTD, as observed in controls [23, 24] . In particular, our results are consistent with recent results showing that the transition to amyloidosis in the population without substantive neurodegeneration is greatest between 60 and 75 years of age [25] . In patients with clinical FTD and antemortem PiB-PET imaging, we confirm pathologic Ab deposition in all patients with a high PiB retention, and the absence of pathologic Ab deposition in 91% (10/11) of cases with a low PiB retention. Importantly, we demonstrate a strong regional correlation between the volume fraction of histological Ab with PiB SUVRs scaled to the white matter, but not to the cerebellum and pons. Almost all patients with FTD undergo PiB-PET imaging before the age of 75 years, and we demonstrate here that in these patients that do not have a pathologic diagnosis of AD, a significantly lower volume fraction of histological Ab is found compared with the patients that have a pathologic diagnosis of AD. Together, this study corroborates the accuracy of PiB-PET imaging in clinical FTD.
Although it is well established that PiB-PET imaging enables the in vivo detection of Ab burden in individuals, it is less clear as to whether PiB-PET imaging selectively binds to fibrillar Ab in neuritic plaques only, or if it also binds to fibrillar Ab in diffuse plaques [5, 6, [26] [27] [28] . Importantly, this contention underscores the lack of pathologic data on Ab in FTD. By assessing a large pathologic series of 108 autopsied cases without a pathologic diagnosis of AD, the present study demonstrates that Ab deposition occurs in w37% (35/ 94) of FTD and 57% (8/14) of age-matched controls early within their 7th decade of life, suggesting incidental Ab plaques in FTD. Despite the younger age at death in patients with a GRN mutation compared to those without, both groups demonstrated a similar proportion of patients with Ab. This converges with emerging evidence of GRN as a risk factor for AD phenotypes and neuropathology [29] to suggest that a GRN mutation may predispose toward Ab deposition, particularly with studies in animal models having shown that GRN haploinsufficiency impairs its inhibitory effect on Ab deposition [30] . In contrast to this, despite the similar age at disease onset and death, Ab deposition was not observed in patients with a MAPT mutation and was only identified in 20% (2/10) of patients with a C9ORF72 expansion. Future studies in larger cohorts of mutation carriers will shed further light on whether these FTD gene mutations protect against or predispose toward Ab deposition. As expected, patients with and without MND or extrapyramidal syndromes demonstrated a similar proportion with Ab deposition.
Amyloidosis represents one of the earliest changes in patients that go on to have intermediate or high levels of AD neuropathology and precedes cognitive impairment by over 15 years [20, 31, 32] . With the use of in vivo markers of Ab deposition, it has been proposed that a diagnosis of preclinical AD can be made even in the absence of cognitive impairment [33, 34] . Importantly, however, although a PiB retention indicative of AD pathology has been reported in patients with clinical FTD [35] , pathologic assessments at autopsy are scarce. In the present series of patients with clinical FTD and high PiB retention (SUVR Cb . 1.5) [20] , we found significant Ab deposition in 100% (4/4) cases, where 75% (3/4) also met neuropathologic criteria for a diagnosis of AD. Importantly, the single case (25%,1/4) who did not meet neuropathologic criteria for a diagnosis of AD [7] , despite all of them fulfilling current clinical research criteria for atypical AD [3] , represents the rare patient with clinical FTD assessed with PiB-PET imaging .75 years of age (Table 2 ). Significant Ab deposition and pathologic AD was identified at postmortem in 9% (1/11) of FTD cases with a low PiB retention (SUVR Cb , 1.5) ( Table 2) , either suggesting significant Ab accumulation in the time that elapsed between PiB-PET imaging and autopsy, which seems unlikely, or, as previously reported, it most likely represents a false negative case [36] . Importantly, we identified a strong regional correlation between the volume fraction of histological Ab and PiB SUVRs scaled to the white matter. Together with the significantly lower cortical burden of Ab identified in FTD cases, these findings attest for the first time, the sensitivity of in vivo measures of Ab in clinical FTD.
The main methodological issue of consideration in the present study is the sample size of the PiB-autopsy cohort. This is one of the larger pathologic evaluations performed in patients with FTD that had undergone in vivo PiB-PET imaging, and our findings support reports in patients with other neurodegenerative conditions [27, 36] . Nevertheless, future studies replicating these findings in larger cohorts of patients with pathologically confirmed FTD will be able to determine the overall sensitivity of PiB-PET imaging in distinguishing between underlying AD and the presence or absence of Ab deposition in FTD syndromes. In comparison to in vivo measures in which an SUVR is derived from both hemispheres, autopsy assessments of Ab are often unilateral and could only be performed in the left hemisphere in this series. As such, although we only identified a strong regional correlation with SUVR scaled to white matter, future studies in larger cohorts or sampling greater predilection sites will determine if histological Ab correlates with SUVR scaled to the cerebellum in FTD, as seen in AD [4] . With the exception of CDR assessments, other more specific neuropsychiatric and cognitive measures were not available for all autopsy cohorts. As such, although Ab is also found in cognitively normal individuals, its contribution to the deterioration in specific cognitive domains in FTD cannot yet be excluded. Finally, given that the present study assessed patients with pathologically confirmed FTD with no or low levels of AD neuropathology, only the milder end of the amyloidosis spectrum may have been represented here and future clinicopathologic studies including cases with AD neuropathology will be needed to determine the clinical progression and ramifications of increasing Ab deposition in FTD. In summary, the present study has assessed for the first time, a large pathologically confirmed series of FTD cases, providing a pathologic reference for the proportion of patients with Ab and the burden of Ab in these patients, which may aid the interpretation of future in vivo assessments of Ab in FTD syndromes. We confirm for the first time, a strong correlation between in vivo and postmortem measures of Ab in FTD. Future pathologic assessments in larger cohorts of patients with FTD that have undergone PiB-PET imaging, and have been followed longitudinally to autopsy, will enable further refinement of current thresholds for in vivo markers of Ab in FTD syndromes and represent an important avenue for future research.
RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the literature using PubMed. There have been several studies assessing amyloid b (Ab) using amyloid imaging in patients with frontotemporal dementia (FTD), but pathologic assessments of Ab in large autopsy-confirmed FTD cohorts are lacking. All relevant citations are appropriately cited.
2. Interpretation: Our findings demonstrate a strong correlation between in vivo and postmortem measures of Ab in FTD and provide a pathologic reference that will assist in the interpretation of future in vivo assessments of Ab in FTD syndromes.
3. Future direction: Future clinicopathologic studies in larger cohorts will be needed to determine the clinical progression and ramifications of increasing Ab deposition in FTD.
